Development of Biodegradable Controlled Release Scleral Systems of Triamcinolone Acetonide

被引:8
|
作者
Blatsios, G. [1 ,2 ]
Tzimas, A. S. [2 ]
Mattheolabakis, G. [3 ]
Panagi, Z. [3 ]
Avgoustakis, K. [3 ]
Gartaganis, S. P. [2 ]
机构
[1] Med Univ Innsbruck, Univ Clin Ophthalmol & Optometry, Dept Ophthalmol & Optometry, Innsbruck, Austria
[2] Univ Patras, Dept Ophthalmol, Sch Med, Rion, Greece
[3] Univ Patras, Pharmaceut Technol Lab, Dept Pharm, Rion, Greece
关键词
Aqueous; Biodegradable; Controlled release; Eye; Poly(lactide); Scleral; Triamcinolone; Vitreous; DIABETIC MACULAR EDEMA; TRANSSCLERAL DRUG-DELIVERY; INTRAVITREAL TRIAMCINOLONE; INTRASCLERAL IMPLANT; NEOVASCULAR DISEASES; TRABECULAR MESHWORK; SUSTAINED-RELEASE; OCULAR BARRIERS; CROSS-LINKING; MG;
D O I
10.3109/02713683.2010.497599
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To develop scleral controlled-release-systems of triamcinolone acetonide (TA) based on biodegradable poly(lactide) (PLA). Materials and Methods: (1) PLA microspheres containing TA were prepared by a single or double emulsification-solvent evaporation method. Morphology, size, effect of drug input and method of microsphere preparation on drug loading, and in vitro TA release of the microspheres were investigated. (2) Mini-tablets consisting of blank PLA-microspheres and TA (weight ratios of 1:1, 2:1, and 4:1, respectively) were developed and their release profile in vitro was evaluated. (3) The in vitro transscleral diffusion profile was evaluated by placing a PLA-TA (1:1) tablet in a donor chamber and measuring the TA concentration in a receptor chamber. Donor and receptor chambers were separated by rabbit sclera. (4) Two cadaver rabbit eyes received a 1:1 PLA-TA tablet episclerally, which was covered by a scleral patch. TA aqueous humor and vitreous concentrations were measured 5, 10, and 20 days post implantation. Results: (1) Microsphere average size was 2 mu m. The double emulsification method and increasing drug input led to an increase in drug loading and encapsulation. Sustained release of TA over several days from the microspheres in vitro was observed, with the rate of release being affected by their TA content. (2) TA exhibited sustained release profile from the PLA-TA tablets, with the rate of release being affected by the PLA: TA ratio. (3) TA could slowly cross the sclera tissue in vitro, with approximately 21% of the drug loaded in the donor compartment being diffused through the sclera in 45 days. (4) Following scleral administration of the PLA-TA mini-tablets, TA accumulated in the vitreous and aqueous humor of cadaver eyes. Conclusions: The PLA-TA microspheres and mini-tablets appear promising for the controlled transscleral delivery of TA and justify further investigation.
引用
收藏
页码:916 / 924
页数:9
相关论文
共 50 条
  • [1] Biodegradable scleral implants as new triamcinolone acetonide delivery systems
    Felt-Baeyens, O.
    Eperon, S.
    Mora, P.
    Limal, D.
    Sagodira, S.
    Breton, P.
    Simonazzi, B.
    Bossy-Nobs, L.
    Guex-Crosier, Y.
    Gurny, R.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 322 (1-2) : 6 - 12
  • [2] Trans-scleral diffusion of triamcinolone acetonide
    Mora, P
    Eperon, S
    Felt-Baeyens, O
    Gurny, R
    Sagodira, S
    Breton, P
    Guex-Crosier, Y
    CURRENT EYE RESEARCH, 2005, 30 (05) : 355 - 361
  • [3] Biodegradable scleral implant for intravitreal controlled release of fluconazole
    Miyamoto, H
    Ogura, Y
    Hashizoe, M
    Kunou, N
    Honda, Y
    Ikada, Y
    CURRENT EYE RESEARCH, 1997, 16 (09) : 930 - 935
  • [4] Biodegradable scleral implant for intravitreal controlled release of ganciclovir
    T. Yasukawa
    H. Kimura
    N. Kunou
    H. Miyamoto
    Y. Honda
    Y. Ogura
    Y. Ikada
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2000, 238 : 186 - 190
  • [5] Biodegradable scleral implant for intravitreal controlled release of ganciclovir
    Yasukawa, T
    Kimura, H
    Kunou, N
    Miyamoto, H
    Honda, Y
    Ogura, Y
    Ikada, Y
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2000, 238 (02) : 186 - 190
  • [6] Intraocular Sustained-Release Delivery Systems for Triamcinolone Acetonide
    Saffar Mansoor
    Baruch D. Kuppermann
    M. Cristina Kenney
    Pharmaceutical Research, 2009, 26 : 770 - 784
  • [7] Intraocular Sustained-Release Delivery Systems for Triamcinolone Acetonide
    Mansoor, Saffar
    Kuppermann, Baruch D.
    Kenney, M. Cristina
    PHARMACEUTICAL RESEARCH, 2009, 26 (04) : 770 - 784
  • [8] SCLERAL PLUG OF BIODEGRADABLE POLYMERS FOR A CONTROLLED DRUG RELEASE IN THE VITREOUS
    HASHIZOE, M
    OGURA, Y
    KIMURA, H
    HONDA, Y
    KYO, M
    HYON, SH
    IKADA, Y
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1993, 34 (04) : 1489 - 1489
  • [9] Biodegradable Intrascleral Implant of Triamcinolone Acetonide in Experimental Uveitis
    Shin, Jae Pil
    Park, Yong Chul
    Oh, Ji Hae
    Lee, Ji Woong
    Kim, Yu Mi
    Lim, Jeong Ok
    Kim, Si Yeol
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2009, 25 (03) : 201 - 207
  • [10] SCLERAL PLUG OF BIODEGRADABLE POLYMERS FOR CONTROLLED DRUG-RELEASE IN THE VITREOUS
    HASHIZOE, M
    OGURA, Y
    KIMURA, H
    MORITERA, T
    HONDA, Y
    KYO, M
    HYON, SH
    IKADA, Y
    ARCHIVES OF OPHTHALMOLOGY, 1994, 112 (10) : 1380 - 1384